| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sukhwinder K Bhullar, Naranjan S Dhall. Adaptive and maladaptive roles of different angiotensin receptors in the development of cardiac hypertrophy and heart failure. Canadian journal of physiology and pharmacology. 2023-09-25. PMID:37748204. |
this hormone is known to induce cardiac hypertrophy and heart failure and its actions are mediated by the interaction of both pro- and anti- hypertrophic ang ii receptors ( at1r and at2r). |
2023-09-25 |
2023-10-07 |
human |
| Shen Bin, Feng Xinyi, Pan Huan, Zhang Xiaoqin, Wu Jiming, He Yi, Li Ziyue, Zou Xiaochun, Lu Zhouqi, Zhou Bangwei, Jin Jing, Liu Shihui, Jinlai Ga. SOX4 as a potential therapeutic target for pathological cardiac hypertrophy. European journal of pharmacology. 2023-09-23. PMID:37741429. |
we found that the sox4 expression was elevated in hypertrophic hearts and angiotensin ii (ang ii)-treated neonatal rat cardiomyocytes (nrcms), and knocking down the sox4 expression in nrcms and mouse hearts significantly reduced the hypertrophic response. |
2023-09-23 |
2023-10-07 |
mouse |
| Teng Sun, Yu Han, Jia-Lei Li, Shuang Wang, Zhi-Jie Jing, Zi Yan, Lan Zhou, Lin Zuo, Jun-Li Yang, Ji-Min Ca. Synaptotagmin-7 Mediates Cardiac Hypertrophy by Targeting Autophagy. The FEBS journal. 2023-09-19. PMID:37724442. |
mir-93 protected hearts against ang ii-induced hypertrophy through targeting syt7-autophagy pathway. |
2023-09-19 |
2023-10-07 |
mouse |
| Qianwen Huang, Qian Huan. Inhibition of lncRNA DANCR Prevents Heart Failure by Ameliorating Cardiac Hypertrophy and Fibrosis Via Regulation of the miR-758-3p/PRG4/Smad Axis. Journal of cardiovascular translational research. 2023-09-01. PMID:37656414. |
it was discovered that prg4 silencing attenuated cell hypertrophy and fibrosis and inactivated the smad pathway under ang ii treatment. |
2023-09-01 |
2023-09-07 |
rat |
| Qian Liu, Cheng Xu, Jing Jin, Wenxiang Li, Jingjia Liang, Shijie Zhou, Zhenkun Weng, Yong Zhou, Xudong Liao, Aihua G. Early-life exposure to lead changes cardiac development and compromises long-term cardiac function. The Science of the total environment. 2023-08-31. PMID:37652374. |
the results showed early-life lead exposure predisposed offspring mice to decreased ejection fraction, increased left ventricular volume, accompanied by hypertrophy and dilation, cardiomyocyte sarcomere dysplasia, abnormal mitochondrial structure, mitochondrial dysfunction, and decreased expression of key sarcomeric and mitochondrial genes, rendering them more susceptible to cardiac hypertrophy, vascular wall thickening, cardiac fibrosis, apoptosis, and heart failure induced by ang ii infusion. |
2023-08-31 |
2023-09-07 |
mouse |
| Jiahe Xie, Cankun Zheng, Mengjia Shen, Weiling Lu, Mingjue Li, Mingyuan He, Lu Chen, Siyuan Ma, Yingqi Zhu, Hairuo Lin, Jiancheng Xiu, Wangjun Liao, Jianping Bin, Yulin Lia. Pregnancy-induced physiological hypertrophic preconditioning attenuates pathological myocardial hypertrophy by activation of FoxO3a. Cellular and molecular life sciences : CMLS. vol 80. issue 9. 2023-08-25. PMID:37626241. |
the pluripara mice whose pregnancy-induced physiological hypertrophy regressed and the nulliparous mice underwent angiotensin ii (ang ii) infusion or transverse aortic constriction (tac). |
2023-08-25 |
2023-09-07 |
mouse |
| Jiahe Xie, Cankun Zheng, Mengjia Shen, Weiling Lu, Mingjue Li, Mingyuan He, Lu Chen, Siyuan Ma, Yingqi Zhu, Hairuo Lin, Jiancheng Xiu, Wangjun Liao, Jianping Bin, Yulin Lia. Pregnancy-induced physiological hypertrophic preconditioning attenuates pathological myocardial hypertrophy by activation of FoxO3a. Cellular and molecular life sciences : CMLS. vol 80. issue 9. 2023-08-25. PMID:37626241. |
compared with nulliparous mice, pathological cardiac hypertrophy induced by ang ii infusion, or tac was significantly attenuated and heart failure induced by tac was markedly improved in mice with php. |
2023-08-25 |
2023-09-07 |
mouse |
| Xi Zheng, Fuxiang Su, Ming Lei, Jingyuan Li, Chenyang Zhang, Yujia Zhang, Ming Wei, Wei Li, Sichong Chen, Yunzhu Liu, Qinghua Gao, Liying Ha. The novel peptide athycaltide-1 attenuates Ang II-induced pathological myocardial hypertrophy by reducing ROS and inhibiting the activation of CaMKII and ERK1/2. European journal of pharmacology. 2023-08-11. PMID:37567457. |
the novel peptide athycaltide-1 attenuates ang ii-induced pathological myocardial hypertrophy by reducing ros and inhibiting the activation of camkii and erk1/2. |
2023-08-11 |
2023-08-16 |
mouse |
| Xi Zheng, Fuxiang Su, Ming Lei, Jingyuan Li, Chenyang Zhang, Yujia Zhang, Ming Wei, Wei Li, Sichong Chen, Yunzhu Liu, Qinghua Gao, Liying Ha. The novel peptide athycaltide-1 attenuates Ang II-induced pathological myocardial hypertrophy by reducing ROS and inhibiting the activation of CaMKII and ERK1/2. European journal of pharmacology. 2023-08-11. PMID:37567457. |
the purpose of this research was to explore the molecular mechanism of a novel peptide athycaltide-1 (ath-1) in the treatment of ang ii-induced pathological myocardial hypertrophy. |
2023-08-11 |
2023-08-16 |
mouse |
| En Ma, Celiang Wu, Jinxiao Chen, Da Wo, Dan-Ni Ren, Hongwei Yan, Luying Peng, Weidong Zh. Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-08-04. PMID:37541173. |
resveratrol prevents ang ii-induced cardiac hypertrophy by inhibition of nf-κb signaling. |
2023-08-04 |
2023-08-14 |
Not clear |
| En Ma, Celiang Wu, Jinxiao Chen, Da Wo, Dan-Ni Ren, Hongwei Yan, Luying Peng, Weidong Zh. Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-08-04. PMID:37541173. |
aberrant activation of angiotensin ii (ang ii)/at1r signaling pathway is one of the main triggers of cardiac hypertrophy, which further gives rise to excessive inflammation that is mediated by the key transcription factor nf-κb. |
2023-08-04 |
2023-08-14 |
Not clear |
| En Ma, Celiang Wu, Jinxiao Chen, Da Wo, Dan-Ni Ren, Hongwei Yan, Luying Peng, Weidong Zh. Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-08-04. PMID:37541173. |
resveratrol (rev) is a natural polyphenol with multiple anti-inflammatory and anti-oxidative effects, however the ability of rev in preventing ang ii-induced cardiac hypertrophy in combination with nf-κb signaling activation remains unclear. |
2023-08-04 |
2023-08-14 |
Not clear |
| Yi-Na Jiang, Shou-Xing Yang, Xuan Guan, Qiaoying Chen, Lin Zhao, Xiao-Yu Yu, Fang-Fang Ren, Shu-Jie Wu, Lian-Pin Wu, Teng-Fang Lai, Lei L. Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway. Biochimica et biophysica acta. Molecular basis of disease. 2023-07-24. PMID:37488049. |
in this study, we found that usp22 was elevated in hypertrophic mouse hearts and in angiotensin ii (ang ii)-induced cardiomyocytes. |
2023-07-24 |
2023-08-14 |
mouse |
| Yi-Na Jiang, Shou-Xing Yang, Xuan Guan, Qiaoying Chen, Lin Zhao, Xiao-Yu Yu, Fang-Fang Ren, Shu-Jie Wu, Lian-Pin Wu, Teng-Fang Lai, Lei L. Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway. Biochimica et biophysica acta. Molecular basis of disease. 2023-07-24. PMID:37488049. |
molecular analysis revealed that transforming growth factor-β-activating protein 1 (tak1)-(jnk1/2)/p38 signaling pathway and hif-1α was activated in the ang ii-induced hypertrophic cardiomyocytes, whereas hif-1α expression was decreased after the inhibition of usp22. |
2023-07-24 |
2023-08-14 |
mouse |
| Chantelle Thimm, Lars Erichsen, Wasco Wruck, James Adjay. Unveiling Angiotensin II and Losartan-Induced Gene Regulatory Networks Using Human Urine-Derived Podocytes. International journal of molecular sciences. vol 24. issue 13. 2023-07-14. PMID:37445727. |
elevated ang ii levels lead to a pro-fibrotic, inflammatory, and hypertrophic milieu that induces apoptosis in podocytes. |
2023-07-14 |
2023-08-14 |
human |
| Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Sara Pelucchi, Gianpaolo Zerbini, Gianluca Perseghin, Giovanni Zatti, Cira R T di Gioi. Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation. International journal of molecular sciences. vol 24. issue 13. 2023-07-14. PMID:37445888. |
ang ii increased blood pressure, myocardial hypertrophy, fibrosis, inflammatory infiltrates and tyrosine hydroxylase expression, as compared to the control group. |
2023-07-14 |
2023-08-14 |
rat |
| Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Sara Pelucchi, Gianpaolo Zerbini, Gianluca Perseghin, Giovanni Zatti, Cira R T di Gioi. Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation. International journal of molecular sciences. vol 24. issue 13. 2023-07-14. PMID:37445888. |
empagliflozin administration prevented the development of myocardial hypertrophy, fibrosis, inflammatory infiltrates and tyrosine hydroxylase overexpression in ang ii-treated rats, without affecting blood glucose and the ang ii-dependent increase in blood pressure. |
2023-07-14 |
2023-08-14 |
rat |
| Jingyao Yang, Long Li, Xiaoxiao Zheng, Zhaoyang Lu, Hua Zho. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-07-08. PMID:37421782. |
however, the underlying mechanism of dapa on angiotensin ii (ang ii)-induced myocardial hypertrophy has never been evaluated. |
2023-07-08 |
2023-08-14 |
mouse |
| Jingyao Yang, Long Li, Xiaoxiao Zheng, Zhaoyang Lu, Hua Zho. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-07-08. PMID:37421782. |
in this study, we not only investigated the effects of dapa on ang ii-induced myocardial hypertrophy, but explored its underlying mechanisms. |
2023-07-08 |
2023-08-14 |
mouse |
| Jingyao Yang, Long Li, Xiaoxiao Zheng, Zhaoyang Lu, Hua Zho. Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 165. 2023-07-08. PMID:37421782. |
in addition, dapa treatment significantly alleviated ang ii-induced elevation of the ratio of heart weight to tibia length, as well as cardiac injury and hypertrophy. |
2023-07-08 |
2023-08-14 |
mouse |